VMO1

Across TCGA pan-cancer cohorts, VMO1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated VMO1 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher VMO1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated VMO1 expression acts as an unfavorable survival marker.

ACC, STAD, and LUAD are the cancer types where VMO1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
STAD	OS	Median	III,IV	0.184	0.641	.011	6	view →
LUAD	DFS	Median	All	0.218	0.676	.014	6	view →
THCA	DFS	Median	All	0.222	0.843	.017	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

VMO1–ACC (DFS)

Open the ACC breakdown →